Remoxy Time-Release Oxycodone Phase III Trial Planned For Year-End
Executive Summary
Pain Therapeutics plans to initiate a Phase III trial for Remoxy, its time-release oxycodone, around year-end
You may also be interested in...
Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs
Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies
Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs
Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies
OxyContin Generics From Endo And Teva Will Include Risk Management Plans
Risk management programs for Endo's and Teva's generic versions of OxyContin reflect differences in the nature of generic marketing compared to that for branded drugs